Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


23.12.2018

1 Am J Surg
2 Ann Surg Oncol
5 BMC Cancer
3 Br J Cancer
3 Breast Cancer (Dove Med Press)
1 Breast Cancer Res
7 Breast Cancer Res Treat
2 Breast J
2 Cancer
2 Cancer Cell
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Res
4 Clin Cancer Res
1 Eur Radiol
2 Int J Cancer
4 J Biol Chem
1 Lancet Oncol
2 Mod Pathol
1 Nat Rev Clin Oncol
1 NPJ Breast Cancer
1 Oncogene
1 Oncol Rep
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Surg


  1. Discussion of: A novel modality for intraoperative margin assessment and its impact on re-excision rates in breast conserving surgery.
    Am J Surg. 2018;215:404-405.
    PubMed     Text format    


    Ann Surg Oncol

  2. TEVIS SE, Bassett R, Bedrosian I, Barcenas CH, et al
    OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients.
    Ann Surg Oncol. 2018 Dec 17. pii: 10.1245/s10434-018-7059.
    PubMed     Text format     Abstract available

  3. ADESOYE T, Schumacher J, Greenberg CC
    ASO Author Reflections: Use of Breast Imaging After Treatment for Locoregional Breast Cancer (AFT-01).
    Ann Surg Oncol. 2018 Dec 18. pii: 10.1245/s10434-018-7070.
    PubMed     Text format    


    BMC Cancer

  4. SALIMI M, Wang R, Yao X, Li X, et al
    Activated innate lymphoid cell populations accumulate in human tumour tissues.
    BMC Cancer. 2018;18:341.
    PubMed     Text format     Abstract available

  5. BALEKOUZOU A, Yin P, Bekolo CE, Pamatika CM, et al
    Histo-epidemiological profile of breast cancers among women in the Central African Republic: about 174 cases.
    BMC Cancer. 2018;18:387.
    PubMed     Text format     Abstract available

  6. DEFOSSEZ G, Quillet A, Ingrand P
    Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers.
    BMC Cancer. 2018;18:393.
    PubMed     Text format     Abstract available

  7. MARMARA D, Marmara V, Hubbard G
    A national cross-sectional study of adherence to timely mammography use in Malta.
    BMC Cancer. 2018;18:346.
    PubMed     Text format     Abstract available

  8. SCHMID R, Wolf K, Robering JW, Strauss S, et al
    ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro.
    BMC Cancer. 2018;18:1273.
    PubMed     Text format     Abstract available


    Br J Cancer

  9. ROMAN M, Hofvind S, von Euler-Chelpin M, Castells X, et al
    Long-term risk of screen-detected and interval breast cancer after false-positive results at mammography screening: joint analysis of three national cohorts.
    Br J Cancer. 2018 Dec 19. pii: 10.1038/s41416-018-0358.
    PubMed     Text format     Abstract available

  10. LOPEZ-KNOWLES E, Pearson A, Schuster G, Gellert P, et al
    Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
    Br J Cancer. 2018 Dec 19. pii: 10.1038/s41416-018-0345.
    PubMed     Text format     Abstract available

  11. PEGRAM MD, Bondarenko I, Zorzetto MMC, Hingmire S, et al
    PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
    Br J Cancer. 2018 Dec 20. pii: 10.1038/s41416-018-0340.
    PubMed     Text format     Abstract available


    Breast Cancer (Dove Med Press)

  12. TALIB WH, Al-Hadid SA, Ali MBW, Al-Yasari IH, et al
    Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action.
    Breast Cancer (Dove Med Press). 2018;10:207-217.
    PubMed     Text format     Abstract available

  13. SADOUGHI F, Kazemy Z, Hamedan F, Owji L, et al
    Artificial intelligence methods for the diagnosis of breast cancer by image processing: a review.
    Breast Cancer (Dove Med Press). 2018;10:219-230.
    PubMed     Text format     Abstract available

  14. DU Y, Yan T, Zhou L, Yin W, et al
    A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer.
    Breast Cancer (Dove Med Press). 2018;10:201-206.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  15. WU WY, Tornberg S, Elfstrom KM, Liu X, et al
    Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up.
    Breast Cancer Res. 2018;20:153.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  16. JOSEPH C, Arshad M, Kurozomi S, Althobiti M, et al
    Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
    Breast Cancer Res Treat. 2018 Dec 15. pii: 10.1007/s10549-018-05085.
    PubMed     Text format     Abstract available

  17. THEBERGE I, Vandal N, Guertin MH, Perron L, et al
    The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?
    Breast Cancer Res Treat. 2018 Dec 18. pii: 10.1007/s10549-018-05095.
    PubMed     Text format     Abstract available

  18. MALMGREN J, Hurlbert M, Atwood M, Kaplan HG, et al
    Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
    Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05090.
    PubMed     Text format     Abstract available

  19. BUTTON B, Croessmann S, Chu D, Rosen DM, et al
    The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.
    Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05087.
    PubMed     Text format     Abstract available

  20. KIM JH, Yoon KH, Hur H, Park S, et al
    Prevalence of breast cancer-related risk factors in underweight premenopausal women: the Korea National Health and Nutrition Examination Survey IV-VI.
    Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05091.
    PubMed     Text format     Abstract available

  21. DURAN-LOZANO L, Montalban G, Bonache S, Moles-Fernandez A, et al
    Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T.
    Breast Cancer Res Treat. 2018 Dec 14. pii: 10.1007/s10549-018-05094.
    PubMed     Text format     Abstract available

  22. JOHANSSON ALV, Weibull CE, Fredriksson I, Lambe M, et al
    Diagnostic pathways and management in women with pregnancy-associated breast cancer (PABC): no evidence of treatment delays following a first healthcare contact.
    Breast Cancer Res Treat. 2018 Dec 14. pii: 10.1007/s10549-018-05083.
    PubMed     Text format     Abstract available


    Breast J

  23. OLIVEIRA NPD, Guedes TSR, Holanda AM, Reis MA, et al
    Influence of social conditions on the quality of life of female breast cancer survivors.
    Breast J. 2018 Dec 17. doi: 10.1111/tbj.13181.
    PubMed     Text format    

  24. BHANDARI A, Xia E, Wang Y, Wang O, et al
    Laparoscopy-assisted sentinel lymph node dissection in breast cancer patients.
    Breast J. 2018 Dec 14. doi: 10.1111/tbj.13172.
    PubMed     Text format    


    Cancer

  25. BOWER JE, Asher A, Garet D, Petersen L, et al
    Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancer.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31827.
    PubMed     Text format     Abstract available

  26. CHIN AL, Bentley JP, Pollom EL
    The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.
    Cancer. 2018 Dec 19. doi: 10.1002/cncr.31910.
    PubMed     Text format     Abstract available


    Cancer Cell

  27. JESELSOHN R, Bergholz JS, Pun M, Cornwell M, et al
    Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.
    Cancer Cell. 2018;33:173-186.
    PubMed     Text format     Abstract available

  28. LI L, Liang Y, Kang L, Liu Y, et al
    Transcriptional Regulation of the Warburg Effect in Cancer by SIX1.
    Cancer Cell. 2018;33:368-385.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  29. FUNG SM, Wong XY, Lee SX, Miao H, et al
    Performance of Single Nucleotide Polymorphisms in Breast Cancer Risk Prediction Models: A Systematic Review and Meta-analysis.
    Cancer Epidemiol Biomarkers Prev. 2018 Dec 18. pii: 1055-9965.EPI-18-0810.
    PubMed     Text format     Abstract available


    Cancer Res

  30. EL AYACHI I, Fatima I, Wend P, Alva-Ornelas JA, et al
    The WNT10B network is associated with survival and metastases in chemoresistant triple-negative breast cancer.
    Cancer Res. 2018 Dec 18. pii: 0008-5472.CAN-18-1069.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  31. HOWIE LJ, Scher NS, Amiri-Kordestani L, Zhang L, et al
    FDA Approval Summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer.
    Clin Cancer Res. 2018 Dec 14. pii: 1078-0432.CCR-18-3003.
    PubMed     Text format     Abstract available

  32. TURNER NC, Telli ML, Rugo HS, Mailliez A, et al
    A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
    Clin Cancer Res. 2018 Dec 18. pii: 1078-0432.CCR-18-1891.
    PubMed     Text format     Abstract available

  33. HWANG KT, Kim J, Jung J, Chang JH, et al
    Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database.
    Clin Cancer Res. 2018 Dec 17. pii: 1078-0432.CCR-18-2782.
    PubMed     Text format     Abstract available

  34. WILSON HE, Rhodes KK, Rodriguez D, Chahal I, et al
    Human breast cancer xenograft model implicates peroxisome proliferator-activated receptor signaling as driver of cancer-induced muscle fatigue.
    Clin Cancer Res. 2018 Dec 17. pii: 1078-0432.CCR-18-1565.
    PubMed     Text format     Abstract available


    Eur Radiol

  35. LAMEIJER JRC, Coolen AM, Voogd AC, Strobbe LJ, et al
    Frequency and characteristics of contralateral breast abnormalities following recall at screening mammography.
    Eur Radiol. 2018;28:4205-4214.
    PubMed     Text format     Abstract available


    Int J Cancer

  36. ANDERSEN AP, Samsoe-Petersen J, Oernbo EK, Boedtkjer E, et al
    The net acid extruders NHE1, NBCn1 and MCT4 promote mammary tumor growth through distinct but overlapping mechanisms.
    Int J Cancer. 2018;142:2529-2542.
    PubMed     Text format     Abstract available

  37. SUNG H, Guo C, Li E, Li J, et al
    The relationship between terminal duct lobular unit features and mammographic density among Chinese breast cancer patients.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32077.
    PubMed     Text format     Abstract available


    J Biol Chem

  38. MAPES J, Anandan L, Li Q, Neff A, et al
    Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis.
    J Biol Chem. 2018;293:2850-2864.
    PubMed     Text format     Abstract available

  39. KARTHIK IP, Desai P, Sukumar S, Dimitrijevic A, et al
    E4BP4/NFIL3 modulates the epigenetically repressed RAS effector RASSF8 function through histone methyltransferases.
    J Biol Chem. 2018;293:5624-5635.
    PubMed     Text format     Abstract available

  40. MOODY RR, Lo MC, Meagher JL, Lin CC, et al
    Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes.
    J Biol Chem. 2018;293:2125-2136.
    PubMed     Text format     Abstract available

  41. SUN X, Gupta K, Wu B, Zhang D, et al
    Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice.
    J Biol Chem. 2018;293:2841-2849.
    PubMed     Text format     Abstract available


    Lancet Oncol

  42. BURKI TK
    T-DM1 for residual, invasive, HER2-positive breast cancer.
    Lancet Oncol. 2018 Dec 13. pii: S1470-2045(18)30918.
    PubMed     Text format    


    Mod Pathol

  43. STEWART RL, Gulbahce EH, Geiersbach KB, Downs-Kelly E, et al
    Reply to Commentary on 'HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features'.
    Mod Pathol. 2018;31:686.
    PubMed     Text format    

  44. SORSCHER S
    Expanding definitions of HER2 positivity.
    Mod Pathol. 2018;31:685.
    PubMed     Text format    


    Nat Rev Clin Oncol

  45. RICHMAN J, Dowsett M
    Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer.
    Nat Rev Clin Oncol. 2018 Dec 18. pii: 10.1038/s41571-018-0145.
    PubMed     Text format     Abstract available


    NPJ Breast Cancer

  46. ALTAN M, Kidwell KM, Pelekanou V, Carvajal-Hausdorf DE, et al
    Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer.
    NPJ Breast Cancer. 2018;4:40.
    PubMed     Text format     Abstract available


    Oncogene

  47. MARUSIAK AA, Prelowska MK, Mehlich D, Lazniewski M, et al
    Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells.
    Oncogene. 2018 Dec 14. pii: 10.1038/s41388-018-0618.
    PubMed     Text format     Abstract available


    Oncol Rep

  48. KIM MH, Park JW, Lee EJ, Kim S, et al
    C16ceramide and sphingosine 1phosphate/S1PR2 have opposite effects on cell growth through mTOR signaling pathway regulation.
    Oncol Rep. 2018;40:2977-2987.
    PubMed     Text format     Abstract available


    PLoS One

  49. SRIMUNINNIMIT V, Pornpraserthsuk P, Chaiwerawattana A, Kongdan Y, et al
    Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer.
    PLoS One. 2018;13:e0209040.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: